Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue

Cancer Biology and Therapy

Volumn 3, Issue 8, 2004, Pages 719-720

  Acharya, Milin R ^a,b   Figg, William D ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Fludarabine; Histone deacetylase inhibitors; Leukemia; MS 275

Indexed keywords

ANTILEUKEMIC AGENT; CELL CYCLE PROTEIN; HISTONE; HISTONE DEACETYLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NUCLEOSIDE ANALOG; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; FLUDARABINE; HISTONE DEACETYLASE; N (2 AMINOPHENYL) 4 (N (PYRIDIN 3 YLMETHOXYCARBONYL)AMINOMETHYL)BENZAMIDE; N-(2-AMINOPHENYL)-4-(N-(PYRIDIN-3-YLMETHOXYCARBONYL)AMINOMETHYL)BENZAMIDE; PYRIDINE DERIVATIVE; VIDARABINE;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CLINICAL TRIAL; DOWN REGULATION; GENE CONTROL; HUMAN; HUMAN CELL; LEUKEMIA CELL; SHORT SURVEY; SIGNAL TRANSDUCTION; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; LEUKEMIA; METABOLISM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL CYCLE; CELL CYCLE PROTEINS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; LEUKEMIA; PYRIDINES; REACTIVE OXYGEN SPECIES; VIDARABINE;

EID: 16644393214     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.8.1065     Document Type: Short Survey

References (17)

1. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001; 1:194-202.
2. Lee BI, Park SH, Kim JW, Sausville EA, Kim HT, Nakanishi O, et al. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res 2001; 61:931-4.
3. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 2001; 48:S20-6.
4. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002; 62:6108-15.
5. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96:4592-7.
6. Thomas MB, Koller C, Yang Y, Shen Y, O'Brien S, Kantarjian H, et al. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. Leukemia 2003; 17:990-3.
7. Gore SD, Carducci MA. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Investig Drugs 2000; 9:2923-34.
8. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95:3003-7.
9. Lozzio CB, Lozzio BB, Machado EA, Fuhr JE, Lair SV, Bamberger EG. Effects of sodium butyrate on human chronic myelogenous leukaemia cell line K562. Nature 1979; 281:709-10.
10. Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, et al. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 2004; 64:2590-600.
11. Biswal SS, Datta K, Acquaah-Mensah GK, Kehrer JP. Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells. Toxicology 2000; 154:45-53.
12. Jarvis WD, Grant S. The role of ceramide in the cellular response to cytotoxic agents. Curr Opin Oncol 1998; 10:552-9.
13. CIP1/WAF1. Cancer Res 2003; 63:3637-45.
14. Yu C, Subler M, Rahmani M, Reese E, Krystal G, Conrad D, et al. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biol Ther 2003; 2:544-51.
15. Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 2003; 63:2118-26.
16. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003; 102:3765-74.
17. Rosato RR, Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2003; 2:30-7.